[
  {
    "ts": null,
    "headline": "Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029",
    "summary": "Kymera Therapeutics (NASDAQ:KYMR) executives highlighted a sharpened strategic focus on immunology and inflammation at Oppenheimer’s 36th Annual Healthcare Conference, emphasizing progress in its STAT6 degrader KT-621, the start of clinical dosing for its IRF5 program, and a financial position the c",
    "url": "https://finnhub.io/api/news?id=8ae23fedbab2d659a4925ac78341a29906803fcde2ad7cf40474803ee8b06d81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772303535,
      "headline": "Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029",
      "id": 139265873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics (NASDAQ:KYMR) executives highlighted a sharpened strategic focus on immunology and inflammation at Oppenheimer’s 36th Annual Healthcare Conference, emphasizing progress in its STAT6 degrader KT-621, the start of clinical dosing for its IRF5 program, and a financial position the c",
      "url": "https://finnhub.io/api/news?id=8ae23fedbab2d659a4925ac78341a29906803fcde2ad7cf40474803ee8b06d81"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Gilead Sciences (GILD) Valuation As Recent Share Price Momentum Meets Conflicting Fair Value Signals",
    "summary": "Recent performance snapshot for Gilead Sciences (GILD) With no single headline event driving Gilead Sciences (GILD) today, recent price moves and fundamentals offer the main reference points for investors watching the stock’s current setup. The share price has returned 3.6% over the past day and declined 1.6% over the past week, with gains of 6.6% over the past month and 18.4% over the past 3 months, against a last close of US$148.95. See our latest analysis for Gilead Sciences. Looking...",
    "url": "https://finnhub.io/api/news?id=61bcf604e33af9dfaebe08585fa443f617259e7739e1540002ed424463cfa1ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772302463,
      "headline": "Assessing Gilead Sciences (GILD) Valuation As Recent Share Price Momentum Meets Conflicting Fair Value Signals",
      "id": 139265874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Recent performance snapshot for Gilead Sciences (GILD) With no single headline event driving Gilead Sciences (GILD) today, recent price moves and fundamentals offer the main reference points for investors watching the stock’s current setup. The share price has returned 3.6% over the past day and declined 1.6% over the past week, with gains of 6.6% over the past month and 18.4% over the past 3 months, against a last close of US$148.95. See our latest analysis for Gilead Sciences. Looking...",
      "url": "https://finnhub.io/api/news?id=61bcf604e33af9dfaebe08585fa443f617259e7739e1540002ed424463cfa1ed"
    }
  },
  {
    "ts": null,
    "headline": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
    "summary": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
    "url": "https://finnhub.io/api/news?id=70d1f60145dc5d34c3a46f1b5cca72e4c80f57870a091a466ae46368aa1ad457",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772266200,
      "headline": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
      "id": 139262332,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=70d1f60145dc5d34c3a46f1b5cca72e4c80f57870a091a466ae46368aa1ad457"
    }
  }
]